WACKER BIOSOLUTIONS
In 2021, WACKER BIOSOLUTIONS grew its sales 20.4 percent to €296.4 million (2020: €246.1 million), chiefly due to volume growth in biologics and cyclodextrins, and to improved prices. Exchange-rate effects dampened sales growth slightly. Sales increased across all regions.
At €38.6 million, EBITDA was at the prior-year level (2020: €38.1 million). Integration costs for the new site in San Diego, California (USA) reduced EBITDA. The EBITDA margin was 13.0 percent (2020: 15.5 percent).
Capital expenditures rose 68.3 percent year over year to €33.5 million (2020: €19.9 million), with one point of focus being expansion of the production plant in Amsterdam. The takeover of Genopis Inc. in the USA broadened WACKER BIOSOLUTIONS’ product portfolio to include pDNA technology and strengthened its presence in the key US biopharmaceutical market.
As of December 31, 2021, the number of employees at the division had decreased to 751 (Dec. 31, 2020: 764 ).
|
|
|
|
|
||||||
€ million |
|
2021 |
|
2020 |
|
2019 |
|
2018 |
|
2017 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
296.4 |
|
246.1 |
|
243.0 |
|
227.0 |
|
205.9 |
EBITDA |
|
38.6 |
|
38.1 |
|
31.1 |
|
23.5 |
|
37.5 |
EBITDA margin (%) |
|
13.0 |
|
15.5 |
|
12.8 |
|
10.4 |
|
18.2 |
EBIT |
|
20.7 |
|
21.6 |
|
14.0 |
|
9.8 |
|
26.1 |
Capital expenditures |
|
33.5 |
|
19.9 |
|
13.2 |
|
17.9 |
|
15.7 |
R&D expenses |
|
5.6 |
|
5.7 |
|
6.4 |
|
6.3 |
|
6.0 |
Employees (December 31, number) |
|
751 |
|
764 |
|
754 |
|
709 |
|
533 |
